January 13, 2022

Scorpion Therapeutics Enters Agreement with AstraZeneca to Discover, Develop and Commercialize Novel Cancer Treatments Against ‘Undruggable’ Targets

— Collaboration leverages Scorpion’s integrated platform for up to three highly selective small molecule therapeutics against well-validated transcription factors, in line with its Precision Oncology 2.0...

January 5, 2022

Scorpion Therapeutics Receives BioSpace NextGen Bio “Class of 2022” Recognition

BOSTON, Mass. – January 5, 2022 – Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0...

November 29, 2021

Scorpion Therapeutics Reveals Highly-selective Lead Programs Targeting Mutant PI3Kα and EGFR Exon 20, Two Established Cancer Drivers with Broad Therapeutic Applicability

— Rapid discovery of lead compounds driven by Scorpion’s Precision Oncology 2.0 strategy, and enabled by its fully integrated drug-hunting platform — — Both mutant PI3Kα...

November 22, 2021

Scorpion Therapeutics Announces Appointment of Brian Piper as Chief Financial Officer

BOSTON, Mass. – November 22, 2021 – Scorpion Therapeutics, Inc. (“Scorpion”), a next-generation oncology company whose goal is to develop best- and first-in-class precision medicines for...

October 25, 2021

Scorpion Therapeutics Expands Executive Leadership Team with Three Key Appointments

– Kristin Schuhwerk joins as Chief Operating Officer –  – Andrew Fedder joins as General Counsel –  –  Adam Friedman, M.D., Ph.D. promoted to President, Corporate...

Endpoints (Subscription Required)  |   September 22, 2021

The Endpoints 11: They’ve got mad money and huge ambitions. It’s time to go big or go home

Scorpion Therapeutics was named as one of the 2021 Endpoints 11, a group of the most promising up-and-coming private biotechnology companies.  

September 22, 2021

Scorpion Therapeutics Named to the 2021 Endpoints 11

BOSTON, MA. — September 22, 2021 — Scorpion Therapeutics was selected today as one of this year’s Endpoints 11, a group of the most promising up-and-coming...

STAT (Subscription Required)  |   July 9, 2021

Up and down the ladder: The latest comings and goings

Scorpion Therapeutics hired Axel Hoos as chief executive officer. Previously, he worked at GlaxoSmithKline, where he was senior vice president of R&D governance chair and therapeutic area...

Boston Business Journal  |   July 9, 2021

GSK’s head of oncology jumps to Boston precision medicine startup

Just eight months out of stealth, precision medicine startup Scorpion Therapeutics has netted a big fish in Axel Hoos, the head of oncology at GlaxoSmithKline plc,...

Scrip (Subscription Required)  |   July 7, 2021

GSK’s Oncology R&D Chief Axel Hoos Jumps To Lead Scorpion

Axel Hoos will become the CEO of a Boston-based cancer start-up focusing on targeted precision drugs. He talked to Scrip about the decision to leave GSK after 10...